Format

Send to

Choose Destination
ERJ Open Res. 2018 Dec 21;4(4). pii: 00141-2018. doi: 10.1183/23120541.00141-2018. eCollection 2018 Oct.

Sarcoidosis: patient treatment priorities.

Author information

1
University of Cincinnati Medical Center, Cincinnati, OH, USA.
2
Asociación Nacional de Enfermos de Sarcoidosis, Madrid, Spain.
3
Foundation for Sarcoidosis Research, Chicago, IL, USA.
4
European Lung Foundation, Sheffield, UK.
5
Lungenfibrose Forum Austria, Vienna, Austria.
6
Sarcoïdose Belangenvereniging Nederland (SBN), Valkenburg, The Netherlands.
7
Amici Contro la Sarcoidosi Italia, Bologna, Italy.
8
Deutsche Sarkoidose-Vereinigung e.V. (DSV), Health Policy and Sarcoidosis Research, Meerbusch, Germany.
9
SarcoidosisUK, London, UK.
10
Hopital Avicenne Service de Pneumologie, Bobigny, France.

Abstract

Sarcoidosis patient survey reveals QoL and functionality are required as core outcomes in treatment and care, along with more multidisciplinary working by clinicians and the establishment of specialist sarcoidosis centres in every European country http://ow.ly/DTvt30mQnqc.

Conflict of interest statement

Conflict of interest: R.P. Baughman reports grants from Gilead (grant to study sarcoidosis associated pulmonary hypertension), Bayer (grant to study sarcoidosis associated pulmonary hypertension), National Institutes of Health (grant to study sarcoidosis therapy), Foundation for Sarcoidosis Research (grant to study sarcoidosis) and Genentech (grant to study sarcoidosis associated fibrosis), and grants and personal fees from Mallinckrodt (grant support to study sarcoidosis, consultant and speaker fees), outside the submitted work. Conflict of interest: R. Barriuso has nothing to disclose. Conflict of interest: K. Beyer has nothing to disclose. Conflict of interest: J. Boyd is an employee of the European Lung Foundation. Conflict of interest: J. Hochreiter has nothing to disclose. Conflict of interest: C. Knoet has nothing to disclose. Conflict of interest: F. Martone has nothing to disclose. Conflict of interest: B. Quadder has nothing to disclose. Conflict of interest: J. Richardson is an Employee of SarcoidosisUK – representing sarcoidosis patients in the UK. Conflict of interest: G. Spitzer has nothing to disclose. Conflict of interest: D. Valeyre reports personal fees from Boehringer Ingelheim (member of scientific advisory boards on IPF), Roche (member of scientific advisory boards on IPF), AstraZeneca (presentation in Avancées de pneumologie), and BI and Roche (support for accommodation and transportation at scientific meetings: ERS, ATS and CPLF), outside the submitted work. Conflict of interest: G. Ziosi has nothing to disclose.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center